Literature DB >> 16895285

Clinical manifestations of sarcoidosis among inner-city African-American dwellers.

Gökhan M Mutlu1, Israel Rubinstein.   

Abstract

OBJECTIVES: To characterize clinical, radiographic and physiological features of sarcoidosis among African Americans residing in inner-city Chicago.
METHODS: This is a retrospective review of medical records of 75 African Americans with biopsy-proven sarcoidosis from internal medicine and pulmonary clinics at three inner-city, acute care hospitals in Chicago.
RESULTS: The number of organs involved was 1.77 +/- 0.94 (mean +/- SD). The most common sites for tissue diagnosis were lung (49%), skin (19%) and lymph nodes (16%). Thirty-six (48%) patients had stage-2 and -3 disease on chest x-ray. Electrocardiographic changes and ocular involvement were detected in 23% and 21% of patients, respectively. Nineteen (25%) patients had obstructive defect (FEV1 1.71 +/- 0.78 L/s), 15 (20%) had a restrictive defect [TLC 4.1 +/- 1.2 L (63.9 +/- 9.2% predicted)]. Three patients had both restrictive and obstructive defect. Forced vital capacity and FEV1 declined by 0.26 L and 0.09 L/s per year, respectively, in patients with an obstructive defect. Most patients (91%) were treated with prednisone for 3.8 +/- 3.9 years (range 0-20 years).
CONCLUSIONS: African Americans with sarcoidosis residing in inner-city Chicago express a high rate of chronic progressive disease necessitating corticosteroid therapy. Further studies are warranted to elucidate the reasons underlying this paradigm.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16895285      PMCID: PMC2569462     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  9 in total

Review 1.  Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization.

Authors:  B A Rybicki; M Major; J Popovich; M J Maliarik; M C Iannuzzi
Journal:  Am J Epidemiol       Date:  1997-02-01       Impact factor: 4.897

2.  Course and prognosis of sarcoidosis around the world.

Authors:  L E Siltzbach; D G James; E Neville; J Turiaf; J P Battesti; O P Sharma; Y Hosoda; R Mikami; M Odaka
Journal:  Am J Med       Date:  1974-12       Impact factor: 4.965

3.  Hospital, age, racial, occupational, geographical, clinical and survivorship characteristics in the epidemiology of sarcoidosis.

Authors:  A Z Keller
Journal:  Am J Epidemiol       Date:  1971-09       Impact factor: 4.897

4.  Sarcoidosis in Washington, D. C. Clinical observations in 105 black patients.

Authors:  R C Young; P Y Titus-Dillon; M L Schneider; T G Shelton; R L Hackney; K A Harden
Journal:  Arch Intern Med       Date:  1970-01

5.  Observations on the course and prognosis of sarcoidosis; with special consideration of its intrathoracic manifestations.

Authors:  D Reisner
Journal:  Am Rev Respir Dis       Date:  1967-09

6.  Sarcoidosis severity and socioeconomic status.

Authors:  D L Rabin; M S Richardson; S R Stein; H Yeager
Journal:  Eur Respir J       Date:  2001-09       Impact factor: 16.671

7.  Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications.

Authors:  C J Johns; S A Schonfeld; P P Scott; J B Zachary; M I MacGregor
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

8.  Sarcoidosis in Caucasians, Blacks and Asians in London.

Authors:  W M Edmondstone; A G Wilson
Journal:  Br J Dis Chest       Date:  1985-01

9.  Sarcoidosis mortality in the United States 1979-1991: an analysis of multiple-cause mortality data.

Authors:  N M Gideon; D M Mannino
Journal:  Am J Med       Date:  1996-04       Impact factor: 4.965

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.